TransMedics Group, Inc.
TMDX
Positions held
Your positionsTMDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- TransMedics Group is positioned in the growing medical devices industry, focusing on innovative organ transplant solutions that address significant unmet needs.
- Revenue increased by 9% compared to the prior quarter, reaching $190 million.
- Gross margin improved to 59.6%, up from 58.2% in the previous quarter.
- The company's earnings growth has declined significantly, with a -55.8% change noted in recent reports.
- The stock has a 'Strong Sell' signal with a score of -33.00, indicating bearish market sentiment.
- Current ratio stands at 6.625, suggesting potential liquidity issues despite high revenue growth.
Fundamentals
| Market cap | $2.74B | Enterprise value | $3.13B | Trailing P/E | 20.47 | Forward P/E | 35.05 |
| PEG | 0.69 | Price / book | 5.28 | Beta | 1.93 | Dividend yield | 0.00% |
| Revenue growth | 20.7% | Earnings growth | -55.8% | Gross margin | 58.7% | Operating margin | 12.5% |
| Profit margin | 22.7% | ROE | 36.3% | ROA | 4.3% | Debt / equity | 1.67 |
| Current ratio | 6.63 | Free cash flow | $44.50M | Analyst recommendation | buy | Mean target | $99.82 |
| 52w high | $156.00 | 52w low | $60.11 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $190M | $174M | $161M | $144M | $157M | — |
| Op margin | 12.5% | 7.6% | 13.2% | 16.2% | 23.2% | — |
| Net income | $14.7M | $7.3M | $105M | $24.3M | $34.9M | — |
| Gross margin | 59.6% | 58.2% | 58.1% | 58.8% | 61.4% | — |
| Gross profit | $113M | $101M | $93.4M | $84.6M | $96.6M | — |
| Operating income | $23.7M | $13.3M | $21.3M | $23.3M | $36.6M | — |
- Revenue +9% vs prior quarter ($190M vs $174M).
- Gross margin 59.6% (was 58.2% prior quarter).
- Operating margin expanded to 12.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $605M | $442M | $242M | $93.5M | — |
| Op margin | 17.9% | 8.5% | -11.9% | -33.6% | — |
| Net income | $190M | $35.5M | -$25.0M | -$36.2M | — |
| Gross margin | 59.9% | 59.4% | 63.8% | 69.8% | — |
| Gross profit | $363M | $262M | $154M | $65.3M | — |
| Operating income | $109M | $37.5M | -$28.7M | -$31.4M | — |
Headlines — watch
• [WARN · fundamentals] TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
News
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-02 · TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings
2026-10-02 · TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds
2026-09-29 · TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
2026-09-15 · 2 Stocks Down 28% and 34% to Buy and Hold
2026-09-10 · TransMedics Names Fernando Araujo as CFO; Maintains 2026 Revenue Outlook
2026-09-10 · TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
2026-09-03 · Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
2026-09-03 · Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
2026-08-31 · TransMedics to Present at Upcoming September Investor Conferences
2026-08-18 · TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
2026-08-11 · TransMedics (TMDX) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns